Company intelligence / Profile preview
Arcus Biosciences
Hayward, California, United Statesarcusbio.com ↗
- Ownership
- Public · RCUS
- Employees
- ~644
- Development stage
- Other
01
Overview
Arcus has multiple clinical-stage programs with their lead candidate domvanalimab (anti-TIGIT) in Phase 3 trials for gastric cancer with data readout approaching. Their HIF-2a inhibitor casdatifan has shown promising results in ccRCC with a 34% objective response rate (25% confirmed) and 81% disease control rate in the 100mg cohort. The company is advancing casdatifan into Phase 3 trials (PEAK-1) in 2025 and has completed enrollment for the Phase 3 STAR-221 study in collaboration with Gilead Sciences.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculesMonoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
16 assets15 more assets in the full pipeline.
03
Partnerships
04
Financials
- Market cap
- $2.2B
- Total revenue
- $247M
- Enterprise value
- $1.7B
Beyond the preview
Go deeper on Arcus Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Arcus Biosciences.